MedTrace Logo

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04201574 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2023-06-22

Study results available
· View outcomes & findings →

Summary

Clinical Trial Evaluating the Safety and Tolerability of ALY688 in Subjects with Dry Eye Disease

Conditions

Interventions

DRUG

ALY688 0.1%

ALY688 0.1% Ophthalmic Solution

DRUG

ALY688 0.4%

ALY688 0.4% Ophthalmic Solution

DRUG

Vehicle

Vehicle Ophthalmic Solution

Sponsors & Collaborators

  • Allysta Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Henry Hsu, MD · Allysta Pharmaceutical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-16
Primary Completion
2020-09-15
Completion
2020-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04201574 on ClinicalTrials.gov